
Dr. Guido Boese
CEO, Zendia GmbH
The innovative InfectoTest® diagnostic technology will make a decisive contribution to malaria elimination by enabling the reliable and quantitative detection of low-density infections at the point-of-care
Malaria remains a major global health challenge. The WHO World Malaria Report 2025 estimates 282 million cases and 610,000 deaths in 2024.1 The reported numbers tell only part of the story. Millions infections remain hidden. Low-density, or submicroscopic, malaria infections usually fall below the detection limits of routine microscopy and rapid diagnostic tests. Such infections persist without obvious symptoms and cause ongoing transmission.1
The problem is particularly relevant for pregnant women. In a systematic review of 68 studies, the median proportion of submicroscopic infections among pregnant women testing positive by molecular methods was 58.7%.2 This highlights a diagnostic gap with important implications for maternal health and malaria control.
More sensitive and accessible diagnostics could improve timely treatment decisions, identify otherwise undetected infections and strengthen malaria control programmes
Closing the diagnostic gap
Zendia is developing InfectoTest®, an automated Point-of-Care platform detecting very low-density malaria infections. It combines magnetic enrichment of Plasmodium falciparum parasites in a specially designed test tube with simplified fluorescence microscopy. The system is designed to identify single parasites and deliver automated results within 10 minutes by non-professionals.
Clinical studies conducted in Uganda, Mali and Angola demonstrated clinical sensitivity and specificity of 95–100% with a detection limit of one to two parasites per microlitre of blood.3
Life-saving impact of InfectoTest®
More sensitive and accessible diagnostics could improve timely treatment decisions, identify otherwise undetected infections and strengthen malaria control programmes. InfectoTest® could support antenatal care, reduce low weight births, save children´s lives by timely diagnosis and parasitemia monitoring and help eliminate Malaria in Mass Screening and Treatment (MSAT).4 InfectoTest® combines an affordable diagnostic instrument with disposable sample tubes costing less than US$1.
Invest in a healthier future
Zendia is seeking € 900,000 in investment through FunderNation to support production of device prototypes, further clinical validation towards IVDR approval and the implementation of its commercialisation strategy. Investments start at €100.
[1] WHO (2025). World Malaria Report 2025.
[2] van Eijk, M. (2023). Prevalence of and risk factors for microscopic and submicroscopic malaria infections in pregnancy: a systematic review and meta-analysis. Lancet Glob. Health 11: e1061–e1074.
[3] Kagaya, W. (2025) Low-density Plasmodium falciparum infection: “Even a parasite will turn”. Parasit. Int. 107:103052.
[4] Slater et al. (2015): Assessing the impact of next-generation rapid diagnostic tests on Plasmodium falciparum malaria elimination strategies. Nature 528(7580):S94-101.
Global Cause